158 related articles for article (PubMed ID: 27307393)
1. UK minister lobbied EU for lighter regulation of drugs and devices.
Cohen D
BMJ; 2016 Jun; 353():i3357. PubMed ID: 27307393
[No Abstract] [Full Text] [Related]
2. Differences between medical devices and drugs.
Browning P
Br J Nurs; 2014 Jun 26-Jul 9; 23(12):S28-9. PubMed ID: 25075388
[No Abstract] [Full Text] [Related]
3. European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287.
Flavell DJ; Flavell SU; Sullivan R
Lancet; 2003 Oct; 362(9393):1415. PubMed ID: 14585646
[No Abstract] [Full Text] [Related]
4. British Labour MEP takes over EU medical devices brief.
Watson R
BMJ; 2014 Sep; 349():g5839. PubMed ID: 25248318
[No Abstract] [Full Text] [Related]
5. Regulation of medicines and medical devices: contrasts and similarities.
Parvizi N; Woods K
Clin Med (Lond); 2014 Feb; 14(1):6-12. PubMed ID: 24532735
[TBL] [Abstract][Full Text] [Related]
6. EU and member state medical devices regulation.
Altenstetter C
Int J Technol Assess Health Care; 2003; 19(1):228-48. PubMed ID: 12701954
[TBL] [Abstract][Full Text] [Related]
7. Why doctors should worry about preemption.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
[No Abstract] [Full Text] [Related]
8. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
Mottes LM
Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
[No Abstract] [Full Text] [Related]
9. The regulation of drugs and biologics: fifty years into the future.
Kuhlik BN
Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
[No Abstract] [Full Text] [Related]
10. A safe pair of hands.
Dean E
Nurs Stand; 2014 Jun; 28(39):61. PubMed ID: 24866673
[TBL] [Abstract][Full Text] [Related]
11. The Food and Drug Administration's regulation of dental products.
Pinco RG; Rubin PD
J Clin Dent; 1995; 6(3):165-9. PubMed ID: 8615957
[No Abstract] [Full Text] [Related]
12. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
[No Abstract] [Full Text] [Related]
13. Teaching the elephant to dance: privatizing the FDA review process.
Price EC
Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734
[No Abstract] [Full Text] [Related]
14. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
O'Reilly JT
Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
[No Abstract] [Full Text] [Related]
15. Combination products: modernizing the regulatory paradigm.
Hunter NL; Sherman RE
Nat Rev Drug Discov; 2017 Aug; 16(8):513-514. PubMed ID: 28496147
[TBL] [Abstract][Full Text] [Related]
16. Regulatory aspects of devices.
Wachtel H
Int J Pharm; 2012 Oct; 435(2):142-4. PubMed ID: 22883700
[No Abstract] [Full Text] [Related]
17. Shrinking waters in the safe harbor: has Integra Lifesciences v. Merck turned the tide by narrowing available exempted infringing uses?
Davison AM
Food Drug Law J; 2004; 59(1):79-92. PubMed ID: 15190926
[No Abstract] [Full Text] [Related]
18. Congress Considers Legislation on "21st Century Cures".
Consult Pharm; 2015 Jul; 30(7):424. PubMed ID: 26173195
[No Abstract] [Full Text] [Related]
19. EU law mandates drug testing in children.
Sinha G
J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
[No Abstract] [Full Text] [Related]
20. FDA, off-label use, and informed consent: debunking myths and misconceptions.
Beck JM; Azari ED
Food Drug Law J; 1998; 53(1):71-104. PubMed ID: 11795338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
